Although (NASDAQ: MRNA) is now a somewhat famous biotech, it was a relatively unknown, clinical-stage company just five years ago. Its success in the COVID-19 vaccine market catapulted it to new heights.
However, once the pandemic began subsiding, with a substantial decline in coronavirus-related sales, Moderna's shares suffered. They're down by 25% over the past three years. Is Moderna just a pandemic stock?
Not at all. Let's consider three reasons why investing in the company today is worth it.
Source Fool.com